Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 503.82 | — | — | — | — | — | 88.00 | — | — | — | — | — | — | — | — | — | 4475.93 | 797.29 | 47.82 | 86.09 | 19.88 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +22417.1% | +802.6% | +26.5% | +213.1% | +34.5% | |
| P/B Ratio | 5.33 | 4.84 | 3.80 | 6.11 | 5.69 | 3.90 | 3.75 | 4.07 | 3.85 | 3.59 | 3.76 | 3.47 | 3.54 | 3.92 | 3.42 | 3.59 | 3.14 | 2.18 | 3.09 | 2.34 | 2.59 |
| — | +24.2% | +1.2% | +50.0% | +47.9% | +8.6% | -0.3% | +17.2% | +8.6% | -8.5% | +9.9% | -3.2% | +12.9% | +80.3% | +10.7% | +53.4% | +20.9% | -28.7% | +29.7% | -29.2% | +21.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.1% | — | — | — | — | — | 100.0% | — | — | — | — | — | — | — | — | — | -22196.2% | -4031.7% | -120.9% | -485.7% | -132.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -16647.7% | -453.4% | +55.9% | -154.8% | -232.5% | |
| Operating Margin | -4974.3% | — | — | — | — | — | -969.8% | — | — | — | — | — | — | — | — | — | -28884.8% | -5655.8% | -198.1% | -664.7% | -192.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -14944.3% | -457.6% | +46.2% | -164.9% | -29.7% | |
| Net Margin | -4612.1% | — | — | — | — | — | -867.3% | — | — | — | — | — | — | — | — | — | -28143.9% | -5813.1% | -224.4% | -684.1% | -190.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -14703.6% | -483.2% | +38.0% | -185.9% | -40.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -51.8% | -8.6% | -10.7% | -18.4% | -15.2% | -12.7% | -8.9% | -8.5% | -7.6% | -6.7% | -5.3% | -5.7% | -7.6% | -7.1% | -5.9% | -5.1% | -4.8% | -4.7% | -3.6% | -6.4% | -6.1% |
| — | +32.2% | -19.5% | -118.0% | -99.1% | -89.3% | -68.9% | -47.9% | -1.3% | +6.0% | +10.9% | -12.8% | -56.5% | -51.7% | -64.5% | +20.7% | +20.9% | +43.4% | +48.8% | +8.2% | -28.0% | |
| ROA | -38.9% | -8.3% | -8.6% | -13.2% | -14.2% | -12.0% | -8.4% | -8.0% | -7.3% | -6.4% | -5.1% | -5.5% | -7.1% | -6.8% | -5.7% | -4.9% | -4.7% | -4.6% | -3.5% | -6.1% | -5.7% |
| — | +30.9% | -2.4% | -64.7% | -94.2% | -86.0% | -65.9% | -47.0% | -2.2% | +4.9% | +10.1% | -11.9% | -52.3% | -48.1% | -62.6% | +20.0% | +18.1% | +41.6% | +47.0% | +3.7% | -32.6% | |
| ROIC | -55.3% | -9.6% | -14.2% | -19.3% | -14.9% | -12.8% | -9.0% | -8.7% | -7.7% | -6.7% | -5.4% | -6.0% | -7.3% | -6.8% | -5.6% | -4.9% | -5.3% | -5.3% | -3.2% | -6.8% | -6.8% |
| — | +25.2% | -58.0% | -122.5% | -93.6% | -92.4% | -64.9% | -44.0% | -5.1% | +2.4% | +3.7% | -23.3% | -38.2% | -28.7% | -76.8% | +28.3% | +22.6% | +42.0% | +57.4% | -4.5% | -47.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| — | -62.4% | -54.6% | +14.3% | +21.3% | +15.6% | +4.9% | +1.6% | -29.0% | -33.2% | -30.6% | -18.8% | +81.9% | +78.2% | +11.5% | -3.7% | -27.1% | -26.7% | +32.2% | -22.4% | +202.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.42 | 21.02 | 27.79 | 13.42 | 12.52 | 15.14 | 17.66 | 17.85 | 22.21 | 23.27 | 31.82 | 23.65 | 21.46 | 19.34 | 23.71 | 26.44 | 41.78 | 57.86 | 68.36 | 39.03 | 19.94 |
| — | +38.8% | +57.4% | -24.8% | -43.6% | -35.0% | -44.5% | -24.5% | +3.5% | +20.3% | +34.2% | -10.6% | -48.6% | -66.6% | -65.3% | -32.3% | +109.6% | +225.0% | +177.3% | +217.4% | +73.1% | |
| Quick Ratio | 13.42 | 21.02 | 27.79 | 13.42 | 12.52 | 15.14 | 17.66 | 17.85 | 22.21 | 23.27 | 31.82 | 23.65 | 21.46 | 19.34 | 23.71 | 26.44 | 41.78 | 57.86 | 68.36 | 39.03 | 19.94 |
| — | +38.8% | +57.4% | -24.8% | -43.6% | -35.0% | -44.5% | -24.5% | +3.5% | +20.3% | +34.2% | -10.6% | -48.6% | -66.6% | -65.3% | -32.3% | +109.6% | +225.0% | +177.3% | +217.4% | +73.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -820.95 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XENE stock.
Xenon Pharmaceuticals Inc.'s current P/E is -9.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xenon Pharmaceuticals Inc.'s current operating margin is -4974.3%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xenon Pharmaceuticals Inc.'s business trajectory between earnings reports.